Avaleht › B-raku lümfoom › Texas › Houston
B-raku lümfoom kliinilised uuringud linnas Houston, TX
16 uuringut haiguse B-raku lümfoom jaoks otsivad osalejaid linnas Houston ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
VärbamineVaatlusuuring
- Texas Children's Hospital, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
VärbamineFaas 3
- Md Anderson Cancer Center, Houston
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
VärbamineFaas 2
- MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
VärbamineFaas 1
- MD Anderson Cancer Center, Houston
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
VärbamineFaas 2
- M D Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
VärbamineFaas 2
- Research Site, Houston
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
VärbamineFaas 1/2
- The University of Texas Md Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
VärbamineFaas 1/2
- Research Site, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
VärbamineFaas 1
- Clinical Trial Site, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
VärbamineFaas 1/2
- M D Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
VärbamineFaas 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
VärbamineFaas 1
- The University of Texas M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
VärbamineFaas 2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
VärbamineFaas 1
- MD Anderson Cancer Center, Houston
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
VärbamineFaas 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
VärbamineFaas 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
B-raku lümfoom uuringud teistes linnades
- New York City, NY19 uuringut
- Chicago, IL12 uuringut
- Nashville, TN11 uuringut
- Philadelphia, PA11 uuringut
- Rochester, MN10 uuringut
- Baldwin Park, CA9 uuringut
- Milwaukee, WI9 uuringut
- Cleveland, OH9 uuringut
- Salt Lake City, UT8 uuringut
- Boston, MA8 uuringut
- Columbus, OH7 uuringut
- Pittsburgh, PA7 uuringut
Muud uuringud linnas Houston
- Mitteväikerakuline kopsuvähk145 uuringut
- Rinnavähk126 uuringut
- Vähk (kõik liigid)121 uuringut
- Metastaatiline vähk104 uuringut
- Käär- ja pärasoolevähk102 uuringut
- Munasarjavähk89 uuringut
- Äge müeloidne leukeemia85 uuringut
- Kopsuvähk78 uuringut
- Eesnäärmevähk76 uuringut
- Endomeetriumivähk68 uuringut
- Pankreasevähk61 uuringut
- Melanoom59 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.